MicroRNA expression in breast cancer tumors from Chilean patients.
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA603563 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:We performed microRNA microarrays from total RNA extracted from 47 breast cancer tumors with known BRCA1 protein status to identify potential regulators of BRCA1 expression. BRCA1 positive tumors ( H-score ≥50) were divided into two groups: “BRCA1 intermediate”, defined by an H-score between 50 and 90, both values included, and “BRCA1 positive”, including tumors with H-score above 90
2020-11-01 | GSE144405 | GEO
Project description:MicroRNA profiles of primary breast cancer tumors of systematically untreated and lymph node negative patients
2022-02-04 | GSE126125 | GEO
Project description:Different genes, especially cytokines, have been deregulated in the inflammatory environment of intestinal mucosa in ulcerative colitis patients. The effects of differential gene expression such as immunological factors have been described before, however, there is no evidence of alarmins deregulated by microRNAs impacting on the pathophysiology of UC. Our goal is to study deregulated genes in inflamed mucosa for microRNA pairing in a Chilean cohort of patients. We used microarrays to compare inflamed and non inflamed mucosa from chilean ulcerative colitis patients
2019-10-07 | GSE133060 | GEO
Project description:MicroRNA profiles of 110 primary breast cancer tumors of systematically untreated, lymph node negative and ER positive patients. Half of the patients developed metastasis while 55 patients remained metastasis-free. The miRCURY LNA microRNA array ready-to-spot probe-set was purchased from Exiqon. The set contains capture-probes for 1212 human, 1040 mouse and 679 rat miRNAs based on the miRBase version 16. Probes were spotted in triplets on CodeLink HD (SurModics) activated glass slides and post-processed according to the CodeLink protocol. SUBMITTER_CITATION: Ines Block, Mark Burton, Kristina P. Sørensen, Lars Andersen, Martin J. Larsen, Martin Bak, Søren Cold, Mads Thomassen, Qihua Tan, Torben A. Kruse. Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-128-3p with recurrence in systemically untreated breast cancer. Oncotarget 2018 Jan; 9:9030-9042. https://doi.org/10.18632/oncotarget.24088
2018-02-16 | GSE103161 | GEO
Project description:MicroRNA profiles of primary breast cancer tumors of systematically untreated and lymph node negative patients
| PRJNA521065 | ENA
Project description:Circulating microRNA Biomarker for Detecting Breast Cancer in High-Risk Benign Breast Tumors
| PRJNA934049 | ENA
Project description:We sought to identify circulating microRNAs (miRNAs) from blood plasma that could be used as biomarkers to detect breast cancer existing in high-risk benign breast tumors. Plasma samples were collected from patients with early-stage breast cancer (CA), high- (HB), moderate- (MB), and no-risk (Be) benign tumors. The miRNAs we have identified have the potential to develop into a crucial blood-based screening tool to help monitor the development of breast cancer in benign breast tumors.
2023-04-20 | GSE225117 | GEO
Project description:This SuperSeries is composed of the following subset Series: GSE29173: MicroRNA sequence and expression analysis in breast tumors by deep sequencing [miRNA sequence data] GSE29174: MicroRNA sequence and expression analysis in breast tumors by deep sequencing [mRNA expression array data] MicroRNAs (miRNAs) regulate many genes critical for tumorigenesis. We profiled miRNAs from 11 normal breast tissues, 17 non-invasive, 151 invasive breast carcinomas, and 6 cell lines by in-house-developed barcoded Solexa sequencing. miRNAs were organized in genomic clusters representing promoter-controlled miRNA expression and sequence families representing seed-sequence-dependent miRNA-target regulation. Unsupervised clustering of samples by miRNA sequence families best reflected the clustering based on mRNA expression available for this sample set. Clustering and comparative analysis of miRNA read frequencies showed that normal breast samples were separated from most non-invasive ductal carcinoma in situ and invasive carcinomas by increased miR-21 (the most abundant miRNA in carcinomas) and multiple decreased miRNA families (including mir-98/let-7), with most miRNA changes apparent already in the non-invasive carcinomas. In addition, patients that went on to develop metastasis demonstrated increased expression of mir-423, and triple negative breast carcinomas were most distinct from other tumor subtypes due to up-regulation of the mir-17~92 cluster. However, absolute miRNA levels between normal breast and carcinomas did not reveal any significant differences. We also discovered two polymorphic nucleotide variations among the more abundant miRNAs miR-181a (T19G) and miR-185 (T16G), but we did not identify nucleotide variations expected for classical tumor suppressor function associated with miRNAs. The differentiation of tumor subtypes and prediction of metastasis based on miRNA levels is statistically possible, but is not driven by deregulation of abundant miRNAs, implicating far fewer miRNAs in tumorigenic processes than previously suggested. Refer to individual Series
2011-06-07 | E-GEOD-28884 | biostudies-arrayexpress
Project description:Background MicroRNA expression is frequently dysregulated in cancer and it could be used potentially as a disease classifier and a prognostic tool in cancer. It has been reported that the cancer associated specific microRNAs were stably detected in blood. The objective of this study was to discover a panel of circulating microRNAs as potential ER+/HER2- breast cancer biomarkers. Methods We compared levels of circulating microRNAs in blood samples from 11 ER+/HER2- advanced breast cancer patients with age-matched 5 control subjects by using microarray-based expression profiling. We validated the level of microRNAs by real-time quantitative polymerase cycle reaction (RT-qPCR) in 40 control subjects, 180 early breast cancer patients (EBC), and 52 metastatic breast cancer patients (MBC). Then, we assessed the association between the levels of microRNA and clinical outcomes of ER+/HER2- metastatic breast cancer. Background MicroRNA expression is frequently dysregulated in cancer and it could be used potentially as a disease classifier and a prognostic tool in cancer. It has been reported that the cancer associated specific microRNAs were stably detected in blood. The objective of this study was to discover a panel of circulating microRNAs as potential ER+/HER2- breast cancer biomarkers. Methods We compared levels of circulating microRNAs in blood samples from 11 ER+/HER2- advanced breast cancer patients with age-matched 5 control subjects by using microarray-based expression profiling. We validated the level of microRNAs by real-time quantitative polymerase cycle reaction (RT-qPCR) in 40 control subjects, 180 early breast cancer patients (EBC), and 52 metastatic breast cancer patients (MBC). Then, we assessed the association between the levels of microRNA and clinical outcomes of ER+/HER2- metastatic breast cancer.
2013-12-12 | GSE53179 | GEO